Biogen's research chief Alfred Sandrock to retire
Reuters
Published Nov 15, 2021 08:33PM ET
(Reuters) - Biogen Inc (NASDAQ:BIIB) said on Monday its research chief Alfred Sandrock, who led development of its Alzheimer's disease drug Aduhelm, is leaving the company after a 23-year run.
The company said Sandrock will retire by the end of this year, and Priya Singhal will lead the research & development unit on an interim basis until a permanent successor is identified.
Sandrock has been the face of Biogen's controversial drug Aduhelm, which was approved by U.S. Food and Drug Administration in June for its ability to remove sticky deposits of another protein called amyloid beta - a likely contributor to Alzheimer's.
Many experts have questioned the FDA'S rationale for approving the drug without more definitive proof of benefit.
Sandrock, a Stanford University alumni, joined the drugmaker in 1998. He had served as the chief medical officer for Biogen for about eight years before joining its executive committee in 2015.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.